Clinical trials: Irinotecan, completed
Metastatic Colorectal Cancer
ARQ 197 in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer
ARQ 197 or placebo in combination with irinotecan and cetuximab in participants with metastatic colorectal cancer (CRC), in participants with wild-type KRAS alleles who have failed front-line systemic therapy, to evaluate the…
- Trial name
- NCT01075048
- Testing
- Tivantinib, Cetuximab, Irinotecan
- Where
- 40 sites in United States, France and 3 more
- Volunteers
- 131 people
- Sponsor
- Daiichi Sankyo
Colorectal Cancer
Research on the Treatment of Metastatic Colon Cancer Patients Treated by FOLFOXIRI
Colon cancer with metastase in the diagnose time account for one significant rate and has a increasing trend. The treatment result of this patient group rests modest.
- Trial name
- NCT03504618
- Testing
- FOLFOXIRI
- Where
- Vietnam
- Volunteers
- 39 people
- Sponsor
- Hanoi Medical University
Unspecified Adult Solid Tumor, Protocol Specific
Combination Chemotherapy In Treating Patients With Metastatic or Unresectable Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00005068
- Testing
- fluorouracil, irinotecan hydrochloride, leucovorin calcium
- Where
- United States
- Sponsor
- Mayo Clinic
Patients With Borderline Resectable Pancreatic Cancer
Neoadjuvant FIRINOX for Borderline Resectable Pancreatic Cancer - a Pilot Study
FOLFIRINOX regimen was recently presented at an international oncology meeting and represents a new standard regimen in the treatment of metastatic pancreatic cancer.
- Trial name
- FIRINOX (NCT02148549)
- Testing
- FIRINOX
- Where
- 9 sites in Japan
- Volunteers
- 10 people
- Sponsor
- Wakayama Medical University
Gastro-Oesophageal Cancer
RegoNivo vs Standard of Care Chemotherapy in AGOC
To determine if the regorafenib and nivolumab combination (RegoNivo) improves overall survival compared with current standard chemotherapy options in refractory AGOC.
- Trial name
- INTEGRATEIIb (NCT04879368)
- Testing
- Regorafenib, Nivolumab, Docetaxel
- Where
- 94 sites in United States, Australia and 7 more
- Volunteers
- 462 people
- Sponsor
- Australasian Gastro-Intestinal Trials Group
Gastric Cancer
Phase I/II Study of Oral S-1 Plus Irinotecan in Patients With Advanced Gastric Cancer
To assess the usefulness of irinotecan plus S-1 therapy based on the antitumor effect and survival period. by performing a phase I/II study of this combination in patients with inoperable or with postoperative gastric cancer
- Trial name
- NCT00209638
- Testing
- irinotecan, S-1
- Volunteers
- 24 people
- Sponsor
- Hokkaido Gastrointestinal Cancer Study Group
Pancreatic Cancer
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Unresectable Pancreatic Cancer
RATIONALE: Drugs used in chemotherapy, such as gemcitabine and irinotecan, work in different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00025168
- Testing
- gemcitabine hydrochloride, irinotecan hydrochloride, radiation therapy
- Where
- 7 sites in United States
- Volunteers
- 20 people
- Sponsor
- Wake Forest University Health Sciences
Metastatic Colorectal Cancer
Irinotecan/Oxaliplatin/5-Fluorouracil/Leucovorin/Cetuximab As First Line Treatment In Colorectal Cancer
This study will evaluate the efficacy of FOLOFOXIRI plus Cetuximab combination in young patients with good performance status with unresectable metastatic colorectal cancer.
- Trial name
- NCT00689624
- Testing
- Irinotecan, Leukovorin, Oxaliplatin
- Where
- Greece
- Volunteers
- 30 people
- Sponsor
- University Hospital of Crete
Gastrointestinal Cancer
Implementing Pharmacogenetic Testing in Gastrointestinal Cancers
Pharmacogenomics (PGx) is the study of how genes affect a person's response to drugs. PGx testing for certain genes can help predict the risk of side effects from chemotherapy agents.
- Trial name
- IMPACT-GI (NCT04736472)
- Testing
- Pharmacogenetic test
- Where
- 3 sites in United States
- Volunteers
- 552 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Adult Glioblastoma, Adult Gliosarcoma
Bevacizumab and Irinotecan or Temozolomide in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme or Gliosarcoma
This randomized phase II trial is studying the side effects and how well giving bevacizumab together with irinotecan or temozolomide works in treating patients with recurrent or refractory glioblastoma multiforme or gliosarcoma.
- Conditions
- Adult Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Neoplasm
- Trial name
- NCT00433381
- Testing
- Bevacizumab, Irinotecan Hydrochloride, Temozolomide
- Where
- 93 sites in United States
- Volunteers
- 123 people
- Sponsor
- National Cancer Institute (NCI)
Pancreatic Cancer, Non-small Cell Lung Cancer
Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Chemotherapy in Participants With Advanced Solid Tumors
The primary objective of the study is to determine the maximum tolerated dose of andecaliximab monotherapy and to evaluate the safety and tolerability of andecaliximab (formerly GS-5745) alone and in combination with…
- Conditions
- Pancreatic Cancer, Non-small Cell Lung Cancer, Esophagogastric Cancer, Colorectal Cancer
- Trial name
- NCT01803282
- Testing
- Andecaliximab, Gemcitabine, Nab-paclitaxel
- Where
- 18 sites in United States
- Volunteers
- 236 people
- Sponsor
- Gilead Sciences
Refractory or Recurrent Solid Tumors, Rhabdomyosarcoma
Study Evaluating the Safety and Efficacy of Eribulin Mesilate in Combination With Irinotecan Hydrochloride in Children With Refractory or Recurrent Solid Tumors
The Phase 1 part of the study is conducted to determine the maximum tolerated dose (MTD) and Recommended Phase 2 Dose (RP2D) of eribulin mesilate in combination with irinotecan hydrochloride in pediatric participants with…
- Conditions
- Refractory or Recurrent Solid Tumors, Rhabdomyosarcoma, Non-Rhabdomyosarcoma Soft Tissue Sarcoma, Ewing Sarcoma
- Trial name
- NCT03245450
- Testing
- Eribulin mesilate, Irinotecan hydrochloride
- Where
- 39 sites in France, Germany and 6 more
- Volunteers
- 40 people
- Sponsor
- Eisai Inc.
Esophageal Squamous Cell Carcinoma
Study of Safety & Efficacy of the Combination of LJM716 & BYL719 in Patients With Previously Treated Esophageal Squamous Cell Carcinoma (ESCC)
To study the safety and efficacy of the combination of LJM716 and BYL719 against currently available treatments of physician's choice in previously treated esophageal squamous cell carcinoma patients.
- Trial name
- NCT01822613
- Testing
- LJM716, BYL719, Paclitaxel
- Where
- 13 sites in United States, Belgium and 7 more
- Volunteers
- 48 people
- Sponsor
- Novartis Pharmaceuticals
Cervix Cancer
CAmpto-CISplatine Plus Radiotherapy in Advanced Cervix Cancer : Search of Tolerated Maximum Dose of Campto
Search of maximum tolerated irinotecan dose in association with cisplatin and pelvic radiotherapy in patients with an advanced cervix cancer.
- Trial name
- NCT00251888
- Testing
- campto (irinotecan), cisplatin (cisplatyl)
- Where
- 2 sites in France
- Volunteers
- 15 people
- Sponsor
- ARCAGY/ GINECO GROUP
Small Intestine Adenocarcinoma, Recurrent Small Intestine Cancer
Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy in Treating Patients With Metastatic or Unresectable Locally Advanced Small Bowel Cancer
This phase II trial studies how well giving irinotecan hydrochloride together with oxaliplatin and capecitabine works as first-line therapy in treating patients with metastatic or unresectable locally advanced small bowel cancer.
- Trial name
- NCT00433550
- Testing
- capecitabine, irinotecan hydrochloride, oxaliplatin
- Where
- 115 sites in United States
- Volunteers
- 33 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Cancer, Colon Cancer
PAVES: Pegfilgrastim Anti-vascular Endothelial Growth Factor (VEGF) Evaluation Study
This is a phase 3, randomized, double-blind, placebo-controlled multi-center study evaluating the efficacy of pegfilgrastim to reduce the incidence of febrile neutropenia (FN) in patients with newly diagnosed, locally-advanced or…
- Conditions
- Cancer, Colon Cancer, Colorectal Cancer, Fever
- Trial name
- NCT00911170
- Testing
- Pegfilgrastim, Bevacizumab, Standard Chemotherapy
- Where
- 154 sites in United States, Australia and 15 more
- Volunteers
- 847 people
- Sponsor
- Amgen
Colorectal Cancer
ZD 1839 in Treating Patients With Locally Advanced or Metastatic Colorectal Cancer
RATIONALE: Biological therapies such as ZD 1839 may interfere with the growth of tumor cells and slow the growth of colorectal cancer.
- Trial name
- NCT00030524
- Testing
- gefitinib
- Where
- 2 sites in United States
- Sponsor
- The University of Texas Health Science Center at San Antonio
Neuroblastoma
Combination Chemotherapy, Monoclonal Antibody, and Natural Killer Cells in Treating Young Patients With Recurrent or Refractory Neuroblastoma
This is a safety / feasibility trial evaluating the combination of a humanized anti-GD2 antibody (HU14.18K322A) manufactured at the Children's GMP, LLC at St.
- Trial name
- NCT01576692
- Testing
- Humanized anti-GD2 antibody, Chemotherapy, Cytokines
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- St. Jude Children's Research Hospital
Colorectal Cancer
Phase IIa Study of Nimotuzumab to Treat Colorectal Cancer
Nimotuzumab is an IgG1 humanized monoclonal antibody that recognized an epitope located in the extra cellular domain of the human epidermal growth factor receptor (EGFR).
- Trial name
- NCT05278728
- Testing
- Nimotuzumab, Irinotecan
- Where
- 2 sites in China
- Volunteers
- 31 people
- Sponsor
- Biotech Pharmaceutical Co., Ltd.
Colorectal Neoplasms, Colorectal Carcinoma
ISIS 183750 With Irinotecan for Advanced Solid Tumors or Colorectal Cancer
Background: Irinotecan is a drug that is used to treat colon or rectal cancer. It affects the deoxyribonucleic acid (DNA) of growing cancer cells. It is most often used with other chemotherapy drugs.
- Conditions
- Colorectal Neoplasms, Colorectal Carcinoma, Colorectal Tumors
- Trial name
- NCT01675128
- Testing
- ISIS 183750, Irinotecan
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- National Cancer Institute (NCI)